Tofacitinib versus Biologic Treatments in Moderate-to-Severe Rheumatoid Arthritis Patients Who Have Had an Inadequate Response to Nonbiologic DMARDs: Systematic Literature Review and Network Meta-Analysis

Lignende værker

• Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs
  af: Strand, Vibeke, et al.
  Udgivet: (2015)
• Real-World Comparative Effectiveness of Tofacitinib and Tumor Necrosis Factor Inhibitors as Monotherapy and Combination Therapy for Treatment of Rheumatoid Arthritis
  af: Reed, George W., et al.
  Udgivet: (2019)
• Review of Routine Laboratory Monitoring for Patients with Rheumatoid Arthritis Receiving Biologic or Nonbiologic DMARDs
  af: Rigby, William F. C., et al.
  Udgivet: (2017)
• Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate
  af: Keystone, Edward C, et al.
  Udgivet: (2015)
• Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studies
  af: Fleischmann, Roy, et al.
  Udgivet: (2016)